07 maj: Vildt SUV-koncept fra Lamborghini
09 maj: Pas på de skjulte forsikringer
08-05-2012 07:01:00

Actelion presents its strategy for value creation

Actelion Pharmaceuticals Ltd /

Actelion presents its strategy for value creation

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

ALLSCHWIL/BASEL, SWITZERLAND - 08 May 2012 - Actelion (SIX: ATLN) will today outline the company's three key strategic elements for value creation at an investor event in London.

1)   

Expanding Actelion's leadership in the PAH market

Actelion is well positioned to expand its leadership in the PAH market following the recent successful conclusion of the landmark SERAPHIN morbidity/mortality study with macitentan in patients suffering from pulmonary arterial hypertension.  

Actelion's new product pipeline in PAH also includes selexipag, a novel prostacyclin-IP receptor agonist, currently evaluated in a Phase III morbidity/mortality study.

2)   

Refocusing R&D on specialty areas

Actelion will refocus its future R&D activities towards specialty markets. Actelion's current clinical pipeline in immunomodulation and antibiotics provides the company with an opportunity to build a second specialty business franchise, thus accelerating revenue growth and diversifying Actelion's risk profile.

3)   

Accelerating cost saving initiatives

Refocusing of Actelion's research and development efforts into specialty areas is expected to result in lower and more targeted R&D spending, as well as lower overhead costs. This is in addition to Actelion's ongoing cost saving program.

Financial Outlook: The execution of Actelion's strategy for value creation is expected - unforeseen events excluded - to produce stable core earnings in 2013 (in local currencies), followed by a return to growth in 2014 and accelerating to double digit growth in 2015.

Jean-Paul Clozel, MD and Chief Executive Officer of Actelion commented: "I am committed to value creation for our shareholders. After the promising macitentan results, Actelion will more than ever continue its effort in the PAH market. The strength of our pipeline and our renewed efforts to optimize profitability will produce a bright future for Actelion."

The complete company update presentation is scheduled in London on Tuesday, 08 May 2012, at 10.00 CEST/ 09.00 BST/ 4.00 a.m. EST and is also made available on the company website, www.actelion.com.

###

Company Update Conference Call / Audiocast details:

Date/Time:

08 May 2012        10.00 hrs - 11.30 hrs          Basel (CEST)

                                09.00 hrs - 10.30 hrs          UK (BST)

                                04.00 a.m. - 5.30 a.m.       US (EST)

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial:                        Europe: +41 (0)44 580 00 74

                                UK:         +44 (0)203 367 94 53

                                US:         +1 866 907 59 23

Participant's mode:

Listen-Only

Audiocast Access:

Audiocast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.

If you experience any access problems go directly to the URL: http://view-w.tv/p/120-121-11206/en

Participant's mode:

Listen only

Audiocast Replay:

The archived Investor Audiocast will be available for replay through http://www.actelion.com approximately 60 minutes after the call has ended.

Actelion Ltd.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,500 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).

For further information please contact:

Roland Haefeli

Senior Vice President, Head of Investor Relations & Public Affairs

Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil

+41 61 565 62 62

+1 650 624 69 36

www.actelion.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates",  "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks",  "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions.  Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Press Release PDF


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE

HUG#1609568

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
14 apr
BAVA
Som det nok er mange bekendt, er kursen på Bavarians aktie faldet meget betydeligt, ca. 30%, over de..
31
19 apr
 
Et opgør med Finanstilsynet er tvingende nødvendigt, hvis tilliden til markedet ikke skal lægges øde..
25
15 apr
OMXC25
Virkelig intelligent indlæg. En masse om at markedet er på vej til nedtur, men sjovt nok ikke så meg..
24
18 apr
 
LÆS NU FOR HELVEDE NOGEN AF DE 38000 indlæg som siger at børsen er nede!   Det er kraftstejleme da u..
21
19 apr
BAVA
      Vedr. shortsqeeze mm. og den ekstreme kursmanipulation der dagligt foregår på Nasdaq Kbhvn. T..
19
14 apr
OMXC25
Følgende er oplæg til debat, om aktiernes udviklign de kommende måneder ud fra handelskrig og naturl..
17
18 apr
 
Det er en katastrofe ! Hvis det fortsætter ret meget længere er vi allesammen nødt til at gå ud og l..
16
17 apr
LAUR
An aktie man aldrig skal eje. Ejerne trækker store summer ud, at en virksomhed der kæmper for overle..
14
19 apr
 
Hej alle,   Jeg lavede et lille indlæg på Stolt-Nielsen for nylig hvor jeg desværre – og det beklage..
13
14 apr
 
Ikke et ord om regimeskifte i Syrien. Dette var et klart defineret og afgrænset angreb på det syrisk..
13

Bavarian: Udenlandske kapitalfonde øger væddemålet på kursfald

20-04-2018 16:36:15
En række kapitalfonde har onsdag og torsdag øget sine shortpositioner i biotekselskabet Bavarian Nordic. Det viser en række indberetninger til Finanstilsynet. Torsdag har Capital Partners øget sin shortposition til 0,62 pct. af aktierne fra 0,54 pct. Ligeledes har AHL Partners øget sin shortposition til 1,31 pct. af Bavarian-aktierne. Tidligere havde kapitalfonden shortet 1,20 pct.Arrow Street øge..

Vestas-konkurrent sælger flere vindmøller - men prispresset fortsætter

20-04-2018 12:49:56
Den amerikanske Vestas-konkurrent General Electric (GE) har solgt flere vindmøller i første kvartal, men selskabet melder om fortsat prispres i branchen. GE havde i de første tre måneder af 2018 en ordreindgang på 936 vindmøller mod 589 i samme periode sidste år. Selskabet oplyser ikke størrelsen på de solgte møller, men skriver i en kommentar, at det har haft en stærk vækst i USA målt på megawatt..

Brøndby-aktien banker til vejrs efter sejr over guldrival

20-04-2018 09:20:41
Aktien i Brøndby IF bliver sendt til vejrs med en stigning på 13,6 pct. til 1,25 kr. fredag morgen, efter at fodboldklubben torsdag aften vandt 3-2 på udebane over FC Midtjylland i Alka Superligaen.Med sejren fastholder Brøndby IF sin førsteplads i Alka Superligaen og har nu tre point ned til netop FC Midtjylland på andenpladsen. Der mangler at blive spillet seks runder, før sæsonen er slut i Alka..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Tyder på flad åbning med Vestas i fokus
2
Vestas/SHB: Sænker anbefaling og kursmål - NY
3
Vestas/SHB: Sænker anbefaling og kursmål
4
Brøndby-aktien banker til vejrs efter sejr over guldrival
5
Vestas-konkurrent sælger flere vindmøller - men prispresset fortsætter

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. april 2018 20:04:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180417.1 - EUROWEB6 - 2018-04-20 20:04:06 - 2018-04-20 20:04:06 - 1 - Website: OKAY